Empathx Clinical Research has joined hyperCORE International's global partner site network, expanding clinical research capabilities across multiple therapeutic areas and geographic regions. The Tampa Bay-based organization operates eight clinical trial sites across California, Florida, Massachusetts, Michigan, Missouri, and Texas, focusing on advancing trials in cardio-metabolic disease, central nervous system disorders, nephrology, and infectious disease.
The partnership brings together two organizations with complementary strengths in clinical research execution. Empathx's unique hybrid model combines dedicated research centers with integrated sites embedded within specialized physician practices, bringing clinical trials directly into environments where patients already receive treatment. This approach aims to expand patient access to trials while supporting efficient study execution through established clinical relationships.
CEO Dustin Owen emphasized that joining hyperCORE reflects a shared commitment to collaboration and quality among leading research site networks. "Joining hyperCORE is about partnering with like-minded, high quality site networks with similar mission," Owen stated. "The partnership enhances our ability to work with sponsors to bring life-changing therapies to our communities. Our added scale, geographic coverage, and access to diverse patient populations gives sponsors a reliable solution for delivering on clinical trials."
For hyperCORE International, the addition of Empathx strengthens an already substantial network. Nicholas Focil, President of hyperCORE International, noted that "Empathx Clinical Research brings a strong blend of therapeutic expertise, geographic reach, and innovative site integration to our partner network. Their approach to embedding research in clinical care aligns with hyperCORE's mission to expand patient access and deliver high-quality trials."
The partnership has significant implications for pharmaceutical companies and biotech sponsors seeking efficient clinical trial execution. With hyperCORE International operating more than 80 active trial sites across five countries and having completed over 7,000 studies involving more than 140,000 randomized participants, the addition of Empathx's specialized sites creates a more comprehensive solution for sponsors. The network's harmonized operational frameworks support consistent trial execution while maintaining the independence of partner organizations.
This expansion comes at a critical time for clinical research, as the industry seeks more efficient ways to conduct trials and reach diverse patient populations. The integration of research into clinical care settings addresses several persistent challenges in clinical trials, including patient recruitment barriers and the disconnect between research and routine medical practice. By embedding trials within existing care environments, the partnership may accelerate the development of new therapies while making clinical research more accessible to patients who might not otherwise participate.
The business implications extend beyond immediate trial execution capabilities. For leaders in pharmaceutical development and healthcare innovation, this partnership represents a strategic alignment that could influence how clinical research networks evolve. The combination of geographic reach, therapeutic specialization, and integrated care models creates a template for future collaborations in the clinical research space. As hyperCORE International continues to expand its network through partnerships like this one, the entire clinical research ecosystem may see increased efficiency and improved patient access to innovative treatments.
